Literature DB >> 12860572

Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis.

Florent Richy1, Olivier Bruyere, Olivier Ethgen, Michel Cucherat, Yves Henrotin, Jean-Yves Reginster.   

Abstract

OBJECTIVE: To assess the structural and symptomatic efficacy of oral glucosamine sulfate and chondroitin sulfate in knee osteoarthritis through independent meta-analyses of their effects on joint space narrowing, Lequesne Index, Western Ontario MacMaster University Osteoarthritis Index (WOMAC), visual analog scale for pain, mobility, safety, and response to treatment.
METHODS: An exhaustive systematic research of randomized, placebo-controlled clinical trials published or performed between January 1980 and March 2002 that assessed the efficacy of oral glucosamine or chondroitin on gonarthrosis was performed using MEDLINE, PREMEDLINE, EMBASE, Cochrane Database of Systematic Reviews, Current Contents, BIOSIS Previews, HealthSTAR, EBM Reviews, manual review of the literature and congressional abstracts, and direct contact with the authors and manufacturers of glucosamine and chondroitin. Inclusion, quality scoring, and data abstraction were performed systematically by 2 independent reviewers who were blinded to sources and authors. Conservative approaches were used for clear assessment of potential efficacy.
RESULTS: Our results demonstrated a highly significant efficacy of glucosamine on all outcomes, including joint space narrowing and WOMAC. Chondroitin was found to be effective on Lequesne Index, visual analog scale pain, mobility, and responding status. Safety was excellent for both compounds.
CONCLUSIONS: Our study demonstrates the structural efficacy of glucosamine and indistinguishable symptomatic efficacies for both compounds. Regarding the relatively sparse data on glucosamine and joint space narrowing and the absence of data on structural effects of chondroitin, further studies are needed to investigate the relationship among time, dose, patient baseline characteristics, and structural efficacy for an accurate, disease-modifying characterization of these 2 compounds.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12860572     DOI: 10.1001/archinte.163.13.1514

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  80 in total

1.  [Marketing-based prescribing].

Authors:  Luz Fidalgo García; Ana Gangoso Fermoso; José Manuel Izquierdo Palomares
Journal:  Aten Primaria       Date:  2011-11-10       Impact factor: 1.137

2.  Effect of 12 months treatment with chondroitin sulfate on cartilage volume in knee osteoarthritis patients: a randomized, double-blind, placebo-controlled pilot study using MRI.

Authors:  J-J Railhac; M Zaim; A-S Saurel; J Vial; B Fournie
Journal:  Clin Rheumatol       Date:  2012-06-23       Impact factor: 2.980

Review 3.  State-of-the-art disease-modifying osteoarthritis drugs.

Authors:  Roland W Moskowitz; Michele Hooper
Journal:  Curr Rheumatol Rep       Date:  2005-03       Impact factor: 4.592

Review 4.  [Evidence-based evaluation of study results of symptomatic glucosamine therapy].

Authors:  S Reiter
Journal:  Z Rheumatol       Date:  2005-10       Impact factor: 1.372

Review 5.  Immunological activity of chondroitin sulfate.

Authors:  Toshihiko Toida; Shinobu Sakai; Hiroshi Akiyama; Robert J Linhardt
Journal:  Adv Pharmacol       Date:  2006

6.  Effect of chondroitin sulphate in symptomatic knee osteoarthritis: a multicentre, randomised, double-blind, placebo-controlled study.

Authors:  Bernard Mazières; Michel Hucher; Mohammed Zaïm; Patrick Garnero
Journal:  Ann Rheum Dis       Date:  2007-01-04       Impact factor: 19.103

Review 7.  The continuing story of nutritional supplements and doping infractions.

Authors:  Olivier de Hon; Bart Coumans
Journal:  Br J Sports Med       Date:  2007-11       Impact factor: 13.800

8.  Potential of Raloxifene in reversing osteoarthritis-like alterations in rat chondrocytes: an in vitro model study.

Authors:  Aysegul Kavas; Seda Tuncay Cagatay; Sreeparna Banerjee; Dilek Keskin; Aysen Tezcaner
Journal:  J Biosci       Date:  2013-03       Impact factor: 1.826

9.  Glucosamine supplementation demonstrates a negative effect on intervertebral disc matrix in an animal model of disc degeneration.

Authors:  Lloydine Jacobs; Nam Vo; Joao Paulo Coelho; Qing Dong; Bernard Bechara; Barrett Woods; Eric Hempen; Robert Hartman; Harry Preuss; Judith Balk; James Kang; Gwendolyn Sowa
Journal:  Spine (Phila Pa 1976)       Date:  2013-05-20       Impact factor: 3.468

10.  Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness.

Authors:  B A Biggee; C M Blinn; T E McAlindon; M Nuite; J E Silbert
Journal:  Ann Rheum Dis       Date:  2005-08-03       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.